SCHEMBL3569897

SCHEMBL3569897

C[n+]1ccc2sc(-c3ccc(OCCCCl)cc3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 4/20 0.48
ATP4B P51164 4/20 0.48
HTT P42858 1/20 0.47
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
PKM P14618 1/20 0.42
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
APP P05067 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15166577 0.76 APP (0.46) RAB9AKDM4ENPC1SMN1; SMN2PKM
SCHEMBL3575964 0.76 ATP4A (0.48) ATP4AATP4BHTTRAB9AKDM4E
SCHEMBL4093997 0.72 CYP2C9 (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL15462904 0.71 ATP4A (0.83) ATP4AATP4BRAB9AKDM4ENPC1
SCHEMBL15462905 0.70 HTT (0.77) ATP4AATP4BHTTRAB9ANPC1
SCHEMBL19229535 0.68 ATP4A (0.78) ATP4AATP4BRAB9AKDM4ENPC1
SCHEMBL5831358 0.68 ATP4A (0.78) ATP4AATP4BRAB9AKDM4ENPC1
SCHEMBL5946741 0.68 ATP4A (0.78) ATP4AATP4BRAB9AKDM4ENPC1
SCHEMBL28575528 0.68 SMN1; SMN2 (0.61) RAB9AKDM4ENPC1SMN1; SMN2PKM
SCHEMBL5544172 0.68 ATP4A (0.60) ATP4AATP4BHTTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
EP-2049548-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands HRH3, HRH4, HRH2 ATP4A 1932/4885ATP4B 2173/4885HTT 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.